🔗 Share this article

Former Prime Minister Rishi Sunak has strengthened his call for a focused screening programme for prostate cancer.

During a recently conducted interview, he declared being "persuaded of the immediate need" of introducing such a initiative that would be economical, achievable and "save numerous lives".

His remarks come as the British Screening Authority reevaluates its decision from five years ago against recommending routine screening.

Media reports suggest the authority may maintain its present viewpoint.

Athlete Contributes Voice to Campaign

Olympic cycling champion Sir Chris Hoy, who has late-stage prostate cancer, wants younger men to be screened.

He proposes reducing the eligibility age for obtaining a prostate-specific antigen blood test.

At present, it is not standard practice to healthy individuals who are under 50.

The prostate-specific antigen screening is disputed though. Measurements can elevate for reasons other than cancer, such as inflammation, resulting in misleading readings.

Opponents maintain this can cause unnecessary treatment and side effects.

Focused Screening Initiative

The recommended screening programme would target males between 45 and 69 with a family history of prostate gland cancer and black men, who face increased susceptibility.

This population includes around 1.3 million individuals males in the Britain.

Research projections indicate the system would cost £25m per year - or about £18 per person per individual - akin to intestinal and breast examination.

The estimate envisions 20% of qualified individuals would be invited each year, with a nearly three-quarters uptake rate.

Medical testing (scans and biopsies) would need to expand by almost a quarter, with only a reasonable growth in healthcare personnel, as per the study.

Clinical Professionals Reaction

Several clinical specialists remain uncertain about the benefit of screening.

They argue there is still a chance that patients will be treated for the disease when it is not absolutely required and will then have to endure side effects such as bladder issues and impotence.

One leading urological expert commented that "The problem is we can often identify disease that might not necessitate to be addressed and we end up causing harm...and my concern at the moment is that risk to reward ratio requires refinement."

Individual Experiences

Individual experiences are also affecting the conversation.

One case involves a man in his mid-sixties who, after seeking a blood examination, was detected with the condition at the age of fifty-nine and was told it had metastasized to his pelvic area.

He has since experienced chemical therapy, radiotherapy and endocrine treatment but remains incurable.

The individual endorses testing for those who are potentially vulnerable.

"This is essential to me because of my sons – they are 38 and 40 – I want them checked as quickly. If I had been examined at fifty I am confident I would not be in the circumstances I am currently," he commented.

Future Steps

The Medical Screening Authority will have to evaluate the data and arguments.

While the latest analysis indicates the ramifications for workforce and accessibility of a testing initiative would be manageable, some critics have contended that it would redirect imaging resources from individuals being treated for alternative medical problems.

The ongoing discussion highlights the complex trade-off between timely diagnosis and possible excessive intervention in prostate cancer treatment.